Enliven Therapeutics Short Ratio vs. EBITDA
| ELVN Stock | 24.54 0.87 3.42% |
For Enliven Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Enliven Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Enliven Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Enliven Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Enliven Therapeutics over time as well as its relative position and ranking within its peers.
Enliven |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enliven Therapeutics. If investors know Enliven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enliven Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.89) | Return On Assets (0.21) | Return On Equity (0.31) |
The market value of Enliven Therapeutics is measured differently than its book value, which is the value of Enliven that is recorded on the company's balance sheet. Investors also form their own opinion of Enliven Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Enliven Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enliven Therapeutics' market value can be influenced by many factors that don't directly affect Enliven Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enliven Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enliven Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enliven Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Enliven Therapeutics EBITDA vs. Short Ratio Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Enliven Therapeutics's current stock value. Our valuation model uses many indicators to compare Enliven Therapeutics value to that of its competitors to determine the firm's financial worth. Enliven Therapeutics is rated # 3 in short ratio category among its peers. It is rated below average in ebitda category among its peers . Enliven Therapeutics reported last year EBITDA of (81.93 Million). The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Enliven Therapeutics' earnings, one of the primary drivers of an investment's value.Enliven EBITDA vs. Short Ratio
Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
Enliven Therapeutics |
| = | 21.89 X |
The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Enliven Therapeutics |
| = | (81.93 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Enliven EBITDA Comparison
Enliven Therapeutics is currently under evaluation in ebitda category among its peers.
Enliven Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Enliven Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Enliven Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Enliven Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Enliven Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 141 K | 148.1 K | |
| Operating Income | -83.5 M | -79.4 M | |
| Income Before Tax | -71.6 M | -68 M | |
| Total Other Income Expense Net | 11.9 M | 12.5 M | |
| Income Tax Expense | 1.3 M | 1.4 M | |
| Net Loss | -71.6 M | -68 M | |
| Net Interest Income | 12 M | 12.6 M | |
| Interest Income | 12 M | 12.6 M | |
| Net Loss | -71.6 M | -68 M | |
| Net Loss | -22.3 M | -23.4 M | |
| Change To Netincome | 1.7 M | 1.6 M | |
| Net Loss | (2.01) | (2.11) | |
| Income Quality | 0.86 | 0.62 | |
| Net Income Per E B T | 0.90 | 0.80 |
Enliven Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Enliven Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Enliven Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Enliven Therapeutics' important profitability drivers and their relationship over time.
Use Enliven Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Enliven Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Enliven Therapeutics will appreciate offsetting losses from the drop in the long position's value.Enliven Therapeutics Pair Trading
Enliven Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Enliven Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Enliven Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Enliven Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Enliven Therapeutics to buy it.
The correlation of Enliven Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Enliven Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Enliven Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Enliven Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Enliven Therapeutics position
In addition to having Enliven Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Artificial Intelligence Thematic Idea Now
Artificial Intelligence
Technology companies, funds, and ETFs across multiple industries that are involved in research or development in the field of reasoning, learning, natural language processing and perception as well as its application to science and commerce. This theme may also include entities involved in cybernetics and cognitive brain simulation field. The Artificial Intelligence theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Artificial Intelligence Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Investing Opportunities. To learn how to invest in Enliven Stock, please use our How to Invest in Enliven Therapeutics guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
To fully project Enliven Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Enliven Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Enliven Therapeutics' income statement, its balance sheet, and the statement of cash flows.